Next Article in Journal
Engaging with Raman Spectroscopy to Investigate Antibody Aggregation
Next Article in Special Issue
Molecular Recognition between Aβ-Specific Single-Domain Antibody and Aβ Misfolded Aggregates
Previous Article in Journal / Special Issue
In Silico Methods in Antibody Design
Article Menu

Export Article

Open AccessFeature PaperArticle
Antibodies 2018, 7(3), 23;

OptMAVEn-2.0: De novo Design of Variable Antibody Regions against Targeted Antigen Epitopes

Department of Chemical Engineering, The Pennsylvania State University, State College, PA 16802, USA
Computational and Systems Biology Initiative, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Received: 20 May 2018 / Revised: 28 June 2018 / Accepted: 29 June 2018 / Published: 30 June 2018
(This article belongs to the Collection Computational Antibody and Antigen Design)
Full-Text   |   PDF [3598 KB, uploaded 5 July 2018]   |  


Monoclonal antibodies are becoming increasingly important therapeutic agents for the treatment of cancers, infectious diseases, and autoimmune disorders. However, laboratory-based methods of developing therapeutic monoclonal antibodies (e.g., immunized mice, hybridomas, and phage display) are time-consuming and are often unable to target a specific antigen epitope or reach (sub)nanomolar levels of affinity. To this end, we developed Optimal Method for Antibody Variable region Engineering (OptMAVEn) for de novo design of humanized monoclonal antibody variable regions targeting a specific antigen epitope. In this work, we introduce OptMAVEn-2.0, which improves upon OptMAVEn by (1) reducing computational resource requirements without compromising design quality; (2) clustering the designs to better identify high-affinity antibodies; and (3) eliminating intra-antibody steric clashes using an updated set of clashing parts from the Modular Antibody Parts (MAPs) database. Benchmarking on a set of 10 antigens revealed that OptMAVEn-2.0 uses an average of 74% less CPU time and 84% less disk storage relative to OptMAVEn. Testing on 54 additional antigens revealed that computational resource requirements of OptMAVEn-2.0 scale only sub-linearly with respect to antigen size. OptMAVEn-2.0 was used to design and rank variable antibody fragments targeting five epitopes of Zika envelope protein and three of hen egg white lysozyme. Among the top five ranked designs for each epitope, recovery of native residue identities is typically 45–65%. MD simulations of two designs targeting Zika suggest that at least one would bind with high affinity. OptMAVEn-2.0 can be downloaded from our GitHub repository and webpage as (links in Summary and Discussion section). View Full-Text
Keywords: de novo antibody design; zika envelope protein; computational protein design; specific antigen epitope de novo antibody design; zika envelope protein; computational protein design; specific antigen epitope

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Chowdhury, R.; Allan, M.F.; Maranas, C.D. OptMAVEn-2.0: De novo Design of Variable Antibody Regions against Targeted Antigen Epitopes. Antibodies 2018, 7, 23.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top